Sommaire

Numéro précédent | Numéro suivant

• Editorial

  • ·What Is Reasonable and Necessary for Alzheimer Patients from Randomized Clinical Trials to Clinical Practice?

    Page :331-332

    Lefkos T. Middleton, J. Touchon, B. Vellas

    

• Viewpoint

  • ·«Compounded Interest» in Alzheimer’s Disease: Do New Amyloid-Targeting Treatments Justify Their Use

    Page :333-335

    Cristina Sampaio

     
  • ·Balancing the Conflicting Goals for Treatment of Alzheimer’s Disease with Monoclonal Antibodies

    Page :336-338

    David R. Scrase, N. Budhwar

    Résumé Résumé
  • ·Clinicians’ Perspectives on How Disease Modifying Drugs for Alzheimer’s Disease Impact Specialty Care

    Page :339-341

    Serge Gauthier, Z. Ismail, Z. Goodarzi, K.P. Ng, P. Rosa-Neto

    Résumé Résumé Plan Plan
  • ·When It Comes to Lecanemab (and Donanemab), How Might We Think about ‘Reasonable and Necessary’?

    Page :342-343

    Lon S. Schneider

    

• Point of View

  • ·What Is Reasonable and Necessary for People Living with AD after the FDA Approves a Treatment?

    Page :344-345

    Rachelle S. Doody, S. Skerjanec

    

• Viewpoint

  • ·Defining FDA Approved Treatments as Reasonable and Necessary: Perspectives of Individuals Living with Alzheimer’s Disease and Care Partners

    Page :346-348

    M.C. Carrillo, M. Moreno

    Plan Plan
  • ·Amyloid-targeting New Therapies for Alzheimer’s Disease: A Health Economics Perspective

    Page :349-352

    L. Jönsson, Anders Wimo

    Plan Plan  

• Editorial

  • ·Clinical Implementation of Lecanemab: Challenges, Questions and Solutions

    Page :353-355

    Takeshi Iwatsubo

    
  • ·Appropriate Use Recommendations for Lecanemab

    Page :356

    Michael S. Rafii

    
  • ·Lecanemab: Appropriate Use Recommendations — A Commentary from a European Perspective

    Page :357-358

    Lutz Frölich, F. Jessen

    
  • ·Implications of Emerging Uses of Genetic Testing for Alzheimer’s Disease

    Page :359-361

    Drew Blasco, J.S. Roberts

    Plan Plan

• Review

  • ·Lecanemab: Appropriate Use Recommendations

    Page :362-377

    J. Cummings, L. Apostolova, G.D. Rabinovici, A. Atri, P. Aisen, S. Greenberg, S. Hendrix, D. Selkoe, M. Weiner, R.C. Petersen, S. Salloway, For the Alzheimer’s Disease and Related Disorders Therapeutics Work Group

    Résumé Résumé Plan Plan  

• Commentary

  • ·Clinical Efficacy in Individual Patients Treated with Lecanemab

    Page :378-379

    Serge Gauthier, J. Therriault, P. Rosa-Neto

     

• Editorial

  • ·Expanding the ATN Framework to Further Personalize Therapies

    Page :380

    S. Gauthier, Pedro Rosa-Neto

    

• Special Article

  • ·Adding the Topographical Information from Tau-PET to the A/T/(N) Framework: Steps Towards Staging AD in Vivo

    Page :381-386

    J. Therriault, S. Gauthier, Pedro Rosa-Neto

    Résumé Résumé Plan Plan  

• Review

  • ·White Matter Hyperintensity as a Vascular Contribution to the AT(N) Framework

    Page :387-400

    Kok Pin Ng, J.Y. Shen, H.J. Chiew, A.S.L. Ng, N. Kandiah, P. Rosa-Neto, S. Gauthier

    Résumé Résumé Plan Plan  
  • ·Neuroinflammation Biomarkers in the AT(N) Framework Across the Alzheimer’s Disease Continuum

    Page :401-417

    A. Bieger, A. Rocha, B. Bellaver, L. Machado, L. Da Ros, W.V. Borelli, J. Therriault, A.C. Macedo, T.A. Pascoal, S. Gauthier, P. Rosa-Neto, Eduardo R. Zimmer

    Résumé Résumé Plan Plan  

• CTAD Task Force Paper

  • ·Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force

    Page :418-425

    D. Angioni, O. Hansson, R.J. Bateman, C. Rabe, M. Toloue, J.B. Braunstein, S. Agus, J.R. Sims, T. Bittner, M.C. Carrillo, H. Fillit, C.L. Masters, S. Salloway, P. Aisen, M. Weiner, B. Vellas, S. Gauthier, EU/US/CTAD Task force, Susan Abushakra, Mohammad Afshar, John Alam, Alicia Algeciras-Schimnich, Sandrine Andrieu, Clive Ballard, Amos Baruch, Richard Batrla, Monika Baudler, Joanne Bell, Sasha Bozeat, Dawn Brooks, Tricia Brooks, Szofia Bullain, Jan Burmeister, Min Cho, Emily Collins, Gavin Cook, Jeffrey Cummings, Chris Dague, Susan De Santi, Rachelle Doody, Billy Dunn, Michael Egan, Sven Eriksson, Rianne Esquivel, Tom Fagan, Phyllis Ferrell, Michela Gallagher, Anna-Kaija Grönblad, Avis Hains, Harald Hampel, Nanco Hefting, Suzanne Hendrix, Carole Ho, Helen Hu, Zahinoor Ismail, Daryl Jones, Gene Kinney, Paul Kinnon, Ricky Kurzman, Lars Lannfelt, John Lawson, Nathalie LeBastard, Valérie Legrand, Nicole Lewandowski, Carine Lim, Costantine Lyketsos, Donna Masterman, Ming Lu, Mark Mintun, José Luis Molinuevo, Cecilia Monteiro, Bradford Navia, Tomas Odergren, Gunilla Osswald, Lewis Penny, Michael Pontecorvo, Anton Porsteinsson, Rema Raman, Gesine Respondek, Larisa Reyderman, Sharon Rogers, Paul Rosenberg, Sharon Rosenzweig-Lipson, Mark Roskey, Rubel Carrie, Ziad Saad, Rachel Schindler, Dennis Selkoe, Melanie Shulman, Kaycee Sink, Lisa Sipe, Daniel Skovronsky, Elizabeth Somers, Maria Soto, Johannes Streffer, Pedro Such, Joyce Suhy, Jacques Touchon, Manu Vandijck, Anne White, David Wilson, Wagner Zago, Jin Zhou

    Résumé Résumé Plan Plan

• Review

  • ·Diagnostic Biomarkers of Amyloid and Tau Pathology in Alzheimer’s Disease: An Overview of Tests for Clinical Practice in the United States and Europe

    Page :426-442

    Leonardo Iaccarino, S.C. Burnham, G. Dell’Agnello, S.A. Dowsett, S. Epelbaum

    Résumé Résumé Plan Plan   
  • ·Adult Renal Dysfunction and Risk of Dementia or Cognitive Decline: Brain-Kidney Axis Hypothesis Based on a Systematic Review and Meta-Analysis

    Page :443-452

    H.-C. Chi, Y. Liu, C.-C. Tan, Y.-C. Zhang, L. Tan, Wei Xu

    Résumé Résumé Plan Plan   

• Original Research

  • ·Outreach, Screening, and Randomization of APOE ε4 Carriers into an Alzheimer’s Prevention Trial: A global Perspective from the API Generation Program

    Page :453-463

    T. Walsh, L. Duff, M. -E. Riviere, P.N. Tariot, K. Doak, M. Smith, B. Borowsky, C. Lopez Lopez, P.C. Arratia, F. Liu, I. Scholten, D. Gordon, J. Arbuckle, A. Graf, M. Quinn, J. Ricart, Jessica Langbaum

    Résumé Résumé Plan Plan  
  • ·Combined Evidence for a Long-Term, Clinical Slowing Effect of Multinutrient Intervention in Prodromal Alzheimer’s Disease: Post-Hoc Analysis of 3-Year Data from the LipiDiDiet Trial

    Page :464-470

    Suzanne B. Hendrix, H. Soininen, A. Solomon, P.J. Visser, A.M.J. van Hees, D.S. Counotte, J. Nicodemus-Johnson, S.P. Dickson, K. Blennow, M. Kivipelto, T. Hartmann, LipiDiDiet clinical study group

    Résumé Résumé Plan Plan  
  • ·Cohort Effects in Alzheimer’s Disease Trials: An Empirical Assessment Utilizing Data from the Alzheimer’s Disease Cooperative Study

    Page :471-477

    Adam I. Birnbaum, J.D. Grill, D.L. Gillen

    Résumé Résumé Plan Plan   
  • ·Validation of the CogDrisk Instrument as Predictive of Dementia in Four General Community-Dwelling Populations

    Page :478-487

    S. Kootar, M.H. Huque, R. Eramudugolla, D. Rizzuto, M.C. Carlson, M.C. Odden, O.L. Lopez, C. Qiu, L. Fratiglioni, S.D. Han, D.A. Bennett, R. Peters, Kaarin J. Anstey

    Résumé Résumé Plan Plan  
  • ·Usefulness of Community Pharmacy for Early Detection of Cognitive Impairment in Older People Using the IQ-CODE Questionnaire

    Page :488-496

    L.F. Agüera Ortiz, G. García-Ribas, F. Jordano Luna, M.C. Porras Álvarez, N. Sánchez Marcos, Begoña Soler López, Grupo de estudio NEURAXCARE

    Résumé Résumé Plan Plan  
  • ·Physical Activity Is Associated with Slower Cognitive Decline in Older Adults with Type 2 Diabetes

    Page :497-502

    Yaacov Rabinowitz, R. Ravona-Springer, A. Heymann, E. Moshier, Y. Berman, J. Schwartz, M. Sano, D. Aisenberg, M. Schnaider-Beeri

    Résumé Résumé Plan Plan   
  • ·Pushing through the Barriers: Peer Advice to Increase Physical Activity and Reduce Dementia Risk from Participants in a Massive Open Online Alzheimer’s Focused Course

    Page :503-512

    M.R. Abela, H. Maxwell, A. Bindoff, J. Alty, M. Farrow, K. Lawler

    Résumé Résumé Plan Plan  
  • ·Association of Circulating Caprylic Acid with Risk of Mild Cognitive Impairment and Alzheimer’s Disease in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Cohort

    Page :513-522

    L. Fan, X. Zhu, A.R. Borenstein, X. Huang, M.J. Shrubsole, L.L. Dugan, Qi Dai

    Résumé Résumé Plan Plan   
  • ·Association between Neuropsychological Performance and CSF Profile in Subjective Cognitive Decline: Towards the Diagnosis of Preclinical AD

    Page :523-529

    E. Chipi, G. Bellomo, N. Salvadori, C. Montanucci, L. Gaetani, F. Paolini Paoletti, Lucilla Parnetti

    Résumé Résumé Plan Plan   
  • ·Reproductive Markers in Alzheimer’s Disease Progression: The Framingham Heart Study

    Page :530-535

    Huitong Ding, Y. Li, T.F.A. Ang, Y. Liu, S. Devine, R. Au, P.M. Doraiswamy, Chunyu Liu

    Résumé Résumé Plan Plan   
  • ·A Genetic Validation of the Neurodegeneration Biomarkers Tau-A and Tau-C - A Mendelian Randomization Study

    Page :536-542

    T.M. Axelsen, C. Bager, A. Bihlet, M.A. Karsdal, K. Henriksen, M.H.E. Tang

    Résumé Résumé Plan Plan  
  • ·Association between Longitudinal Cerebrospinal Fluid Alzheimer’s Biomarkers and the Lifestyle for Brain Health (LIBRA) Index: Findings from the European Prevention of Alzheimer’s Dementia Cohort Study (EPAD LCS)

    Page :543-550

    Tyler S. Saunders, M. Protsiv, N.D. Jenkins, A. Solomon, K. Blennow, C. Ritchie, G. Muniz-Terrera

    Résumé Résumé Plan Plan  
  • ·Understanding Online Registry Facilitators and Barriers Experienced by Black Brain Health Registry Participants: The Community Engaged Digital Alzheimer’s Research (CEDAR) Study

    Page :551-561

    Miriam T. Ashford, D. Zhu, J. Bride, E. McLean, A. Aaronson, C. Conti, C. Cypress, P. Griffin, R. Ross, T. Duncan, X. Deng, A. Ulbricht, J. Fockler, M.R. Camacho, D. Flenniken, D. Truran, S.R. Mackin, C. Hill, M.W. Weiner, D. Byrd, R.W. Turner, H. Cham, M. Rivera Mindt, R.L. Nosheny

    Résumé Résumé Plan Plan  
  • ·Subjective Cognitive Complaints: Comparing the Relation between Self-Reported Versus Informant-Reported Subjective Cognitive Complaints and Cognitive Performances in Cognitively Unimpaired, Mild Cognitive Impairment and Populations with Dementia

    Page :562-570

    S.-W. Peng, C.-Y. Wang, S.-Y. Lin, Y.-L. Lee, Y.-C. Lin, Y.-J. Lin, Pei-Ning Wang

    Résumé Résumé Plan Plan   
  • ·Chinese Preclinical Alzheimer’s Disease Study (C-PAS): Design and Challenge from PET Acceptance

    Page :571-580

    L. Cui, L. Huang, F.-F. Pan, Y. Wang, Q. Huang, Y.-H. Guan, C-Y.Z. Lo, Y.-H. Guo, Agnes Suiyin Chan, Fang Xie, Qihao Guo

    Résumé Résumé Plan Plan   
  • ·Neuroprotective Effects of IVIG against Alzheimer’s Disease via Regulation of Antigen Processing and Presentation by MHC Class I Molecules in 3xTg-AD Mice

    Page :581-594

    Z. Fei, B. Pan, R. Pei, S. Ye, Z. Wang, L. Ma, R. Zhang, C. Li, Xi Du, Haijun Cao

    Résumé Résumé Plan Plan   

• Brief Report

  • ·‘Time Saved’ As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings

    Page :595-599

    S.P. Dickson, Alette M. Wessels, S.A. Dowsett, C. Mallinckrodt, J.D. Sparks, S. Chatterjee, S. Hendrix

    Résumé Résumé Plan Plan  
  • ·Ten Years after the National Alzheimer’s Plan: Dementia Remains a Hidden Syndrome in France

    Page :600-606

    J.-F. Dartigues, J.A. Avila-Funes, L. Letenneur, C. Meillon, C. Helmer, H. Amieva, Karine Pérès

    Résumé Résumé Plan Plan  

• Brief Communication

  • ·Associations between Participant Characteristics and Participant Feedback about an Unsupervised Online Cognitive Assessment in a Research Registry

    Page :607-614

    Miriam T. Ashford, J. Eichenbaum, C. Jin, J. Neuhaus, A. Aaronson, A. Ulbricht, M.R. Camacho, J. Fockler, D. Flenniken, D. Truran, R.S. Mackin, P. Maruff, M.W. Weiner, R.L. Nosheny

    Résumé Résumé Plan Plan